摘要
目的:系统评价盐酸小檗碱片治疗非酒精性脂肪性肝病的疗效,以为临床治疗提供循证参考。方法:计算机检索中国期刊全文数据库、万方数据库、中文科技期刊数据库、中国生物医学文献数据库及Pub Med,收集盐酸小檗碱片治疗非酒精性脂肪性肝病的观察性研究,提取资料并进行质量评价后采用Rev Man 5.3统计软件进行Meta分析。结果:共纳入6项研究,合计294例患者。Meta分析结果显示,盐酸小檗碱片可显著降低非酒精性脂肪性肝病患者血清中天冬氨酸氨基转移酶[WMD=18.97,95%CI(2.25,35.70),P=0.03]、丙氨酸氨基转移酶[WMD=31.04,95%CI(7.17,54.91),P=0.01]、甘油三酯[WMD=1.07,95%CI(0.39,1.74),P=0.002]、总胆固醇[WMD=1.31,95%CI(0.79,1.84),P<0.001]水平,治疗前后比较差异均有统计学意义。结论:盐酸小檗碱片可显著改善非酒精性脂肪性肝病患者的肝功能及血脂水平,临床疗效较为确切。受纳入研究方法学质量的限制,该结论有待大样本、高质量的随机对照试验进一步验证。
OBJECTIVE： To systematically review the efficacy of Berberine hydrochloride tablet in the treatment of non-alco- holic fatty liver disease （NAFLD）, and provide evidence-based reference for the clinical treatment. METHODS： Retrieved from CJFD, Wanfang Database, VIP, CBM and PubMed, observational studies about Berberine hydrochloride tablet in the treatment of NAFLD were collected. After data extraction and quality evaluation, Meta-analysis was performed by using Rev Man 5.3 statistics software. RESULTS ： A total of 6 studies were included, involving 294 patients. Results of Meta-analysis showed Berberine hydro- chloride tablet could significantly reduce the levels of AST[WMD=18.97, 95% CI（2.25, 35.70）, P=0.03], ALT[WMD=31.04, 95%CI（7.17,54.91） ,P=0.01], TG[WMD=1.07, 95%CI（0.39, 1.74） ,P=0.002] and TC[WMD= 1.31,95%CI（0.79, 1.84） ,P〈 0.001] in the serum of patients with NAFLD. There were significant differences. CONCLUSIONS： Berberine hydrochloride tablet can significantly improve the liver function and blood lipid levels of patients with NAFLD, and the clinical efficacy is relatively pre- cise. Due to the limit of methodological quality, it remains to be further verified by large-scale and high quality RCT.
出处
《中国药房》
CAS
北大核心
2015年第30期4232-4235,共4页
China Pharmacy
关键词
盐酸小檗碱片
非酒精性脂肪性肝病
疗效
META分析
Berberine hydrochloride tablet
Non-alcoholic fatty liver disease
Efficacy
Meta-analysis
